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ABSTRACT 
The disease diabetes currently affects more than 62 million people which 
is more than 7.1% of India’s adult population. The prevalence rate of 
diabetes in urban and rural areas is 10.3% and 6.2% respectively.  
The Aim of the study is standardization of the method of preparation and 
administration of Somvalk Kashay Asthapan Basti and Somvalk Siddha 
Taila Anuvasan Basti. Two groups Group A (Trial Group) 50 patients is 
given Somvalkkashayasthapan Basti, and Somvalk siddhataila 
anuvasanbasti along with Metformin for 12 days and Group B (Control 
Group) 50 patients is given oral hypoglycemic drug and Metformin will 
be given according to the dosage 12 days. 
Group A showed moderate improvement, while Group B showed no 
improvement. The overall result obtained in the present study  shows 
65% improvement in trial group which is moderate improvement 
according to the overall assessment criteria, whereas there was only 18% 
improvement in the control group which falls within unimproved 
category according to the overall assessment criteria. 
The trial drug in the study i.e., Somvalk kasha Asthapanbasti has been 
proved significantly effective in symptoms like Polyuria, polydipsia, 
polyphagia and urine sugar. It has shown moderate effects on the 
symptoms like numbness and tingling. It has shown mild improvement in 
parameters of BSL- Fasting and BSL- PP. 
 
INTRODUCTION 
The human race is very proudly holding its 
supreme position in this world. This supremacy 
comes partly as a gift from Mother Nature, but 
mostly due to the never ending efforts of the 
human. The modern world is full of examples of 
human intelligence and efforts. But the human has 
paid heavily for this advancement in the form of fast 
growing life style disorders. There is deterioration 
in the quality of life if seen from health point of 
view. In the race to gain supremacy and improved 
quality of life in the form of comforts, people have 
resorted to an unhealthy life style leading to stress, 
depression and various life style related disorders 
like obesity, heart disease and diabetes. 
The theme for World health day 2016 was 
Diabetes. This itself emphasizes the importance, the 
WHO is giving to this disorder. As the prevalence of 
this disorder is increasing at a fast rate, it has 
become a concern for the health community. 
Prevalence of the disease 
According to the latest 2016 data from the 
WHO, about 422 million adults are living with 
diabetes mellitus. India would soon be the Diabetes 
capital of the world with a projected 109 million 
individuals with diabetes by 2035. This disease 
currently affects more than 62 million people which 
is more than 7.1% of India’s adult population.3So, 
such is the picture of diabetes globally and in our 
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country. The prevalence rate of diabetes in urban 
and rural areas are 10.3% and 6.2% respectively. 
This indicates that the modern lifestyle is much 
responsible for the disease. The WHO defines 
diabetes as a chronic disease that occurs either 
when the pancreas does not produce enough insulin 
or when the body cannot effectively use the insulin 
it produces. There are two main types of diabetes. 
In type 1 diabetes, there is no insulin production in 
the body and therefore the patient requires insulin 
injections to survive. In Type 2 diabetes, which 
comprises 90% of the cases, patients are unable to 
use the insulin produced by the body. People with 
type 2 diabetes are typically overweight and are 
sedentary. 
Though there have been many breathtaking 
advancements in the field of health and medicine, 
people are again turning towards the ancient ways 
of treatment and life style as there has been 
realization of the hazardous consequences of the 
fast and unhealthy life style. ‘Ayurveda’ is one such 
ancient ‘science of life’ which has proved its efficacy 
in solving many of the health problems related to 
unhealthy life style. This science of life which was 
originated in India, aims at keeping the healthy 
people healthy and treating the diseased people to 
enable them to lead long and healthy life. 
Panchkarma is the branch which was till 
now considered adjuvant to Kayachikitsa but it has 
now emerged as a separate branch due to its 
importance in curing disease. Panchkarma which 
literally means ‘five therapies’ is a branch which 
deals with the Shodhan treatment. Shodhan means 
cleansing the body off its impurities. It has an upper 
edge on other types of treatments as Shodhan is 
Apunarbhav type of treatment, which means the 
diseases are eliminated along with its root cause 
thus, preventing its recurrence.  
In Ayurveda, the disease called Prameha 
closely resembles diabetes mellitus. It has been 
described by nearly all the authors of ancient Indian 
medicine. The most popular description of Prameha 
is that given by Madhavnidan. The disease which is 
characterized by polyuria is known as Prameha. 
There are 20 types of Prameha described in the 
texts of Ayurveda by different Acharyas. These 
types are mainly based on the color of the urine 
passed by the person. A very detailed description of 
the eitology, pathology and treatment of Prameha is 
given by most of the Acharyas. A sedentary life style 
and wrong food habits (high carbohydrate intake) 
are considered as the main cause of Prameha. 
Need of study: The present study is conducted to 
study the effect of ‘Basti’ procedure of Panchkarma 
which is the most effective modality of treatment 
for Vaatdosha. The drug used for Basti procedure is 
‘Somvalk’ which mainly acts upon Kaphadosha, and 
also has Medoghna property, Meda is the one of the 
Dushyas in Prameha and Kapha is the main Dosha 
involved in pathology of Prameha. Thus the 
combined effect of the drug and Basti therapy is 
expected to yield good results. The reference for the 
present study is taken from Charaksamhita, 
Siddhisthan 10 i.e., ‘Bastisiddhiadhyay’ in which 
Acharya Charak has described Basti medications 
according to various diseases. If this therapy is 
found adequately effective in controlling the blood 
sugar levels and the symptoms arising out of it, it 
can be used alone or in combination with the OHAs 
to give the diabetics relief from the daily painful 
pricks of insulin syringes. Moreover, it can be 
helpful in good control of blood sugar levels and can 
also reduce the dose of OHAs. 
AIM AND OBJECTIVES 
Aim 
To study the role of Somvalk Kashay Asthapan Basti 
in Prameha W.S.R to (Diabetes mellitus Type 2). 
Objectives 
1. Literature review of Somvalk Kashay Asthapan 
Basti and Metformin in Prameha (Diabetes 
mellitus Type 2). 
2. Standardization of the method of preparation 
and administration of Somvalk Kashay Asthapan 
Basti and Somvalk Siddha Taila Anuvasan Basti. 
3. To observe if any adverse reaction occurs 
during the Basti process. 
Materials and Methods 
Materials needed for Basti procedure 
1. Tiltaila for Bahyasnehan before Basti 
2. Nadiswedanyantra for Swedan 
3. Freshly prepared Somvalk kwath 
4. Somvalk siddha taila 
5. Enema apparatus 
6. Glycerine syringe 
7. Rubber catheter 
8. Disposable glove 
Method of Kwath (decoction) Preparation 
The Kwath was prepared as per the 
procedure described by Sharangdhara. 1 Pala 
Somvalk bharad is mixed with 16 times water and it 
is reduced to 1/8th part to get the Kwath. 
Somvalka kwath 
Preparation of Asthapan Basti 
 There is a specific order of mixing various 
ingredients of Niruha Basti as described in Ashtang 
Hruday. First of all Saindhav was added to Madhu 
and mixed properly. Then Tiltaila was added and 
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mixed, followed by Kalka and finally the Kwath was 
added. The whole mixture was mixed thoroughly, 
and was heated to body temperature in a water 
bath. 
Basti Dosage: For an adult person, the standard 
Basti dosage fixed by Charak is 12 Prasruta, which 
comes out be 960 ml. 
Sharangdhara has fixed Bastimatra as follows- 
 Uttammatra -  80 Tola (800ml) 
 Madhyammatra-  64 Tola (640ml) 
 Hinamatra - 48 Tola (480ml) 
In this study the Madhyammatra told by 
Sharangdhara was taken i.e., 640ml. This was done 
keeping in mind the practical difficulties faced my 
majority of patients in retaining large quantity of 
Basti fluid for a desirable period of time. 
The quantity of Sneha in Niruhabasti in 
Kaphapradhanvyadhi is 1/8th of total Bastidravya 
quantity. So, the quantity of Bastidravyas was taken 
as follows. 
Kwath - 5 parts = 400ml 
Sneha -1.5 parts = 120ml 
Kalka -1 part = 80gm 
Saindhav = 10gm 
Madhu = 30ml 
Method of Preparation of Somvalk Siddha Taila 
Somvalk siddhataila, used for Anuvasan 
basti, was prepared according to the following 
method. During the preparation of the Taila, 
Somvalk was used as Kalkadravya. The kwath used 
was also that of Somvalk, while Tiltaila was used as 
Snehadravya. The ingredients with their proportion 
used for the preparation of Somvalk siddha taila is 
as given below- 
Somvalk bharad -  1 part 
Tilataila  -  4 parts 
Somvalk kwath -  16 parts 
Procedure  
1. The Kwath was prepared according to 
reference of Sharangdhara as given above. 
2. Now, the Kwath was mixed with the Tiltaila 
along with the Somvalkkalka in above 
mentioned proportion and subjected to heat. 
3. This mixture was heated till the Sneha siddhi 
lakshanas were observed. 
4. The Somvalk siddha taila thus prepared was 
then cooled and stored for further use. 
Clinical Study: An open controlled clinical study 
was carried out. The patients were diagnosed on 
the basis of sign and symptoms of Prameha 
(Diabetes mellitus type 2) as per Ayruvedic and 
modern diagnostic methods. 
Diagnosis was made with the help of following 
parameters- 
Subjective parameters 
1. Polyuria - Prabhutmutrata 
2. Polydipsia - Pipasaadhikya 
3. Poyphagia -  Kshudha 
4. Burning sensation-  Karpadadaha 
5. Polyneuritis -  Karapadasuptata 
Objective parameters 
1. Blood sugar- Fasting 126mg/dl - 226mg/dl and 
Random 200mg/dl - 300mg/dl 
2. Urine sugar  –  0.05% and above. 
Inclusion criteria 
1. Age between 30-50 years. 
2. Recently diagnosed cases (<1 year) of Diabetes 
mellitus Type II. 
3. Patients with Fasting blood glucose 126mg/dl - 
226mg/dl and 
PP blood glucose 200mg/dl - 300mg/dl 
4. Patient taking Metformin (OHA) as regular 
treatment. 
Exclusion criteria 
1. Age below 30 and above 50 years. 
2. Jataha Prameha. 
3. Other associated complications like 
hypertension, any other CVS or CNS disorder. 
4. Pregnant or lactating women. 
5. Patients taking Insulin or any OHA other than 
Metformin as regular treatment. 
Grouping of patients 
 Total diagnosed 100 no. of patients with 
consent were selected from the OPD and IPD of the 
college hospital. 
Group A-Trial group  
Group B- Control group 
Group Treatment Duration 
Group A (Trial Group) 
50 patients 
Somvalkkashayasthapan Basti, and Somvalk siddha taila 
anuvasanbasti along with Metformin 
12 days 
Group B (Control 
Group) 
50 patients 
Oral hypoglycemic drug, Metformin will be given according 
to the dosage 
12 days 
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Drug administration details: The patients of 
Control Group were asked to continue to take their 
oral hypoglycemic drug Metformin in their 
prescribed dosage and schedule for a period of 12 
days, after the initial diagnostic investigations. 
 The patients of Trial Group were 
administered Somvalk kashay basti and Somvalk 
siddha anuvasan basti along with their oral 
hypoglycemic drug Metformin in their prescribed 
dose and schedule for a period of 12 days, after the 
initial diagnostic investigations. 
Administration of Basti 
 Asthapan basti of Somvalk kwath was 
administered. As per following reference 
 We cannot apply one type of Basti i.e. 
Niruha or Anuvasana continuously. If we apply 
Anuvasana Basti continuously it aggravates morbid 
matter and reduces the Agni i.e. digestive power 
and if we use Niruha Basti then it causes 
provocation of Vata. Thus Niruha after Anuvasana 
or vice versa are very much important to restore 
the body normalcy and to pacify the diseases. 
So, Somvalk siddha taila was used for the 
Anuvaasanbasti which was given after 3 consecutive 
Asthapan basti. 
Poorva karma 
 Proper examination of the patient was carried 
out regarding the state of aggravated Doshas, 
Agni, Bala, Satmya etc. 
 Blood pressure, pulse, respiration rate was 
recorded before the procedure. 
 Sthanikmriduabhyang with Tilataila was done 
on udar-kati-nitamb-jangha-jaanu-paad pradesh 
of the patient. 
 Mridunadiswedan was done on the Abhyang 
parts till the Samyak swedan lakshanas were 
observed.  
Pradhan Karma: The Niruhabasti and Anuvasan 
basti were administered to the patients as per the 
schedule for 12 days. 
 Nirooha Basti- Somvalk kashaybasti (640ml). 
 Anuvasan basti- Somvalk siddha taila (60ml). 
Sr. No Treatment Duration 
1. Snehana and Mridu Swedanpurvak Niruhabasti 1st Day 
2. Snehana and Mridu Swedanpurvak Niruhabasti 2nd Day 
3. Snehana and Mridu Swedanpurvak Niruhabasti 3rd Day 
4. Snehana and Mridu Swedanpurvak Anuvasan basti 4th Day 
5. Snehana and Mridu Swedanpurvak Niruhabasti 5th Day 
6. Snehana and Mridu Swedanpurvak Niruhabasti 6th Day 
7. Snehana and Mridu Swedanpurvak Niruhabasti 7th Day 
8. Snehana and Mridu Swedanpurvak Anuvasan basti 8th Day 
9. Snehana and Mridu Swedanpurvak Niruhabasti 9th Day 
10. Snehana and Mridu Swedanpurvak Niruhabasti 10th Day 
11. Snehana and Mridu Swedanpurvak Niruhabasti 11th Day 
12. Snehana and Mridu Swedanpurvak Anuvasan basti 12th Day 
 Ideally, Anuvasan basti should be retained for 
12hrs. 
 And Niruhabasti should be retained for 48 
minutes. 
 It is then allowed to come out along with fecal 
matter and excess Pitta and Kapha. 
 The patients were instructed to evacuate bowel 
when there is urge of passing stools. Patients 
were instructed not to strain or pass motion 
forcibly or retain forcibly. 
Paschaat karma 
Anuvasan basti- Sphikatadana, Shayaya 
Utkshepana-3 times. 
Niruhabasti: Supine position was given to the 
patient and pillow was placed below the lower back 
region. 
Advice given after the procedure 
1) To take hot water bath after Basti 
Pratyagamana. 
 Anuvasana Bastipratyagamanakaal- 3 Yama 
 Niruhabastipratyagamanakaal - 1 Muhurta 
2) To take normal diet, but less in quantity and 
avoid spicy food. 
3) To avoid heavy work, walking, running, day 
sleep, exercise etc. 
After the administration of Basti, the 
observations were recorded in the Basti record 
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chart every day. The data thus collected was then 
subjected to statistical analysis at the end of the 
clinical trial. 
Following symptom score will be adopted for the 
assessment. 
0- Completely relieved 
1- Mild symptoms present 
2- Moderate symptoms present 
3- Severe symptoms present 
Polyuria (Prabhutmootrata) 
Score Frequency of urine 
0 Frequency of 4-6 times/24 hrs 
1 Frequency of 7-9 times/24 hrs 
2 Frequency of 10-12 times/24 hrs 
3 Frequency of > 13 times/24 hrs 
Polydipsia (Pipasaadhikya) 
Score Assessment criteria 
0 Absent (taking 8-10 glass of water/day) 
1 Taking 10-15 glass of water/day 
2 Taking 15-20 glass of water/day 
3 Unable to have sound sleep due to thirst 
Polyphagia (Kshudhaadhikya) 
Score Assessment Criteria 
0 2 Chapati/meal 
1 3-4 Chapati/meal 
2 4-5 Chapati/meal 
3 >5 Chapati/meal 
Burning sensation of soles and palms (Karapadadaha) 
Score Assessment Criteria 
0 Absent 
1 Occasional 
2 Continuous 
3 Continuous and require medication 
Polyneuritis (Karapadasuptata) 
Score Assessment Criteria 
0 Absent 
1 Occasional 
2 Continuous 
3 Continuous and require medication 
Observations and Result 
Table 1: Distribution according to Age 
Groups Group A Group B Total 
Sr.No. Age Count Percent Count Percent Count Percent 
1 30 - 34  4 8.00%  5 10.00%  9 9.00% 
2 35 - 39  13 26.00%  13 26.00%  26 26.00% 
3 40 - 44  12 24.00%  15 30.00%  27 27.00% 
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Groups Group A Group B Total 
Sr.No. Age Count Percent Count Percent Count Percent 
4 45 - 50  21 42.00%  17 34.00%  38 38.00% 
Total  50 100.00%  50 100.00%  100 100.00% 
In group A, 4 patients (8%) were having age between 30 - 34 years, 13 patients (26%) belonged to 
age group 35 – 39 years, 12 patients (24%) were having age between 40 – 44 while 21 patients (42%) 
belong to age group 45 – 50 years. 
In group B, 5 patients (10%) were having age between 30 - 34 years, 13 patients (26%) belonged to 
age group 35 – 39 years, 15 patients (30%) were having age between 40 – 44 while 17 patients (34%) 
belong to age group 45 – 50 years. 
Table 2: Distribution according to Gender 
Groups Group A Group B Total 
Sr.No. Gender Count Percent Count Percent Count Percent 
1 Male  27 54.00%  30 60.00%  57 57.00% 
2 Female  23 46.00%  20 40.00%  43 43.00% 
Total  50 100.00%  50 100.00% 100 100.00% 
In group A, 27 patients (54%) were male while 23 patients (46%) were female. While in group B, 30 
patients (60%) were male while 20 patients (40%) were female.  
Table 3: Distribution according to Religion 
Groups Group A Group B Total 
Sr.No. Religion Count Percent Count Percent Count Percent 
1 Hindu  48 96.00%  48 96.00%  96 96.00% 
2 Muslim  2 4.00%  2 4.00%  4 4.00% 
Total  50 100.00%  50 100.00% 100 100.00% 
In group A, 48 patients (96%) were Hindu while 2 patients (4%) were Muslim. Whereas in group B 
too, 48 patients (96%) were Hindu while 2 patients (4%) were Muslim.  
Table 4: Distribution according to Habitat 
Groups Group A Group B Total 
Sr.No. Diet Count Percent Count Percent Count Percent 
1 Rural  42 84.00%  44 88.00%  86 86.00% 
2 Urban  8 16.00%  6 12.00%  14 14.00% 
Total  50 100.00%  50 100.00%  100 100.00% 
In group A, 42 patients (84%) were from rural area while 8 patients (16%) were from urban area. 
Whereas, in group B, 44 patients (88%) were from rural area while 6 patients (12%) were from urban.  
Table 5: Distribution according to Diet 
Groups Group A Group B Total 
Sr.No. Diet Count Percent Count Percent Count Percent 
1 Mixed  47 94.00%  44 88.00%  91 91.00% 
2 Vegetarian  3 6.00%  6 12.00%  9 9.00% 
Total  50 100.00%  50 100.00%  100 100.00% 
In group A, 47 patients (94%) were having mixed diet while 3 patients (6%) were vegetarian. 
Whereas, in group B, 44 patients (88%) were having mixed diet while 6 patients (12%) were vegetarian.  
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Table 6: Distribution according to Nature of work 
Groups Group A Group B Total 
Sr.No. Nature of work Count Percent Count Percent Count Percent 
1 Heavy  5 10.00%  9 18.00%  14 14.00% 
2 Medium  19 38.00%  18 36.00%  37 37.00% 
3 Sedentary  26 52.00%  23 46.00%  49 49.00% 
Total  50 100.00%  50 100.00%  100 100.00% 
In group A, 5 patients (10%) were doing heavy work, 19 patients (38%) were concerned with 
medium strenuous work while 26 patients (52%) were having sedentary nature of work. In group B, 9 
patients (18%) were doing heavy work, 18 patients (36%) were concerned with medium strenuous work 
while 23 patients (46%) were having sedentary nature of work. 
Table no: 7 Prakruti wise distribution  
Groups Group A Group B Total 
Sr.No. Prakruti Count Percent Count Percent Count Percent 
1 Vata - Pitta  5 10.00%  8 16.00%  13 13.00% 
2 Vata - Kapha  10 20.00%  8 16.00%  18 18.00% 
3 Pitta - Vata  3 6.00%  0 0.00%  3 3.00% 
4 Pitta - Kapha  9 18.00%  10 20.00%  19 19.00% 
5 Kapha - Vata  10 20.00%  10 20.00%  20 20.00% 
6 Kapha - Pitta  13 26.00%  14 28.00%  27 27.00% 
Total  50 100.00%  50 100.00% 100 100.00% 
In group A, 5 patients (10%) were of Vata – Pitta prakruti, 10 patients (20%) were from Vata – 
Kaphaprakruti, 3 patients (6%) were from Pitta – Vataprakruti, 9 patients (18%) were from Pitta – 
Kaphaprakruti, 10 patients (20%) were of Kapha – Vataprakruti while 13 patients (27%) were of Kapha – 
Pitta prakruti. 
In group B, 8 patients (16%) were of Vata – Pitta prakruti, 8 patients (16%) were from Vata – 
Kaphaprakruti, 10 patients (20%) were from Pitta – Kaphaprakruti, 10 patients (20%) were of Kapha – 
Vataprakruti while 14 patients (28%) were of Kapha – Pitta prakruti.  
Table 8: Socio-economic status 
Groups Group A Group B Total 
Sr.No. Class  Count Percent Count Percent Count Percent 
1 High  37  74%  32 64% 69  69% 
2 Middle   9 18%  10 20% 19  19% 
3 Low   4 8%  8 16% 12  12% 
Total  50 100.00%  50 100.00%  100 100.00% 
In group A, 37 patients (74%) belonged to higher class, 9 patients (18%) belonged to middle class, 
while 4 patients (8%) belonged to lower class. In group B, 32 patients (64%) belonged to higher class, 19 
patients (20%) belonged to middle class, while 8 patients (16%) belonged to lower class. 
Statistical analysis of different parameters: As grading used for some assessment parameters were 
ordinal in nature, “Wilcoxon Signed Rank test” is used for intra-group comparison. (i.e. before and after 
treatment of a group) while for inter-group comparison, (i.e. for comparing two groups with each other) 
“Mann-Whitney U test” is used. For quantitative parameters, intra group comparison is done with “paired t 
test” while for inter-group comparison, “Unpaired t test” is used. 
We have tested hypothesis for each parameter and result is interpreted accordingly. The level of significance 
is kept at 0.05. Proper summary statistics like mean, median, S.D., IQR (Inter Quartile Range) are provided 
along with graphical and diagrams. 
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Table 9: Prabhootmootrata (Polyuria) 
Group 
Mean score 
Median 
diff. 
IQR of 
diff. 
Q3 – Q1 
Sample 
size 
Wilcoxon signed 
rank test (T+) 
P 
Value B.T A.T diff 
Group A 2.54 0.30 2.24 2.00 
1.0  
 (3.0 - 2.0) 
50 1275.00 < 0.001 
Group B 2.36 1.68 0.68 0.50 
1.0  
 (1.0 - 0.0) 
50 340.50 < 0.001 
For group A, the median reduction in Prabhutmootrata score after treatment is significant (P-value < 0.001) 
at 5% level of significance. i.e. it can be said that there is significant reduction in Prabhootmootrata for 
Group A. For group B, the median reduction in Prabhutmootrata score after treatment is significant (P-value 
< 0.001) at 5% level of significance. i.e. in group B too, there is significant reduction in Prabhootmootrata. 
Table 10: Comparative Analysis of Groups 
Group 
Median 
difference 
(bef–aft) 
Mean of 
difference 
(bef-aft) 
S.D. of 
difference 
(bef-aft) 
Mann-
Whitney U 
statistic 
P- Value 
Group A 2.00 2.24 0.66 2241.00 
 
< 0.001 
 Group B 0.50 0.68 0.91 
Reduction in Prabhootmootrata score for group A was significantly higher than that in group B (p –value < 
0.001) at 5% level of significance. Thus, treatment A can be considered as more effective in reducing 
Prabhootmootrata as compared to treatment B.  
Table 11: Gradation wise distribution of patients 
Prabhootmootrata 
0 1 2 3 
No. % No. % No. % No % 
Group A 
BT 0 0.00% 1 2.00% 21 42.00% 28 56.00% 
AT 36 72.00% 13 26.00% 1 2.00% 0 0.00% 
Group B 
BT 0 0.00% 3 6.00% 26 52.00% 21 42.00% 
AT 6 12.00% 7 14.00% 34 68.00% 3 6.00% 
Table 12: Pipaasaadhikya (Polydipsia) 
Group 
Mean score Median 
diff. 
IQR of diff. 
Q3 – Q1 
Sample 
size 
Wilcoxon signed 
rank test (T+) 
P Value 
B.T A.T diff 
Group A 2.34 0.42 1.92 2.00 
0.0  
 (2.0 - 2.0) 
50 1275.00 < 0.001 
Group B 2.24 1.70 0.54 0.00 
1.0  
 (1.0 - 0.0) 
50 231.00 < 0.001 
For group A, the median reduction in Pipaasaadhikya score after treatment is significant (P-value < 0.001) at 
5% level of significance. i.e. it can be said that there is significant reduction in Pipaasaadhikya for Group A. 
For group B, the median reduction in Pipaasaadhikya score after treatment is significant (P-value < 0.001) at 
5% level of significance. i.e. in group B too, there is significant reduction in Pipaasaadhikya. 
Table 13: Comparative Analysis of Groups 
Group 
Median 
difference 
(bef–aft) 
Mean of 
difference 
(bef-aft) 
S.D. of 
difference 
(bef-aft) 
Mann-
Whitney U 
statistic 
P- Value 
Group A 2.00 1.92 0.53 2274.50 
 
< 0.001 
 Group B 0.00 0.54 0.76 
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Reduction in Pipaasaadhikya score for group A was significantly higher than that in group B (p –value < 
0.001) at 5% level of significance. Thus, treatment A can be considered as more effective in reducing 
Pipaasaadhikya as compared to treatment B.  
Table 14: Gradation wise distribution of patients 
Pipaasaadhikya 
0 1 2 3 
No. % No. % No. % No % 
Group A 
BT 0 0.00% 1 2.00% 31 62.00% 18 36.00% 
AT 32 64.00% 15 30.00% 3 6.00% 0 0.00% 
Group B 
BT 0 0.00% 3 6.00% 32 64.00% 15 30.00% 
AT 5 10.00% 6 12.00% 38 76.00% 1 2.00% 
Table 15: Kshudhaadhikya (Polyphagia) 
Group 
Mean score Median 
diff. 
IQR of diff. 
Q3 – Q1 
Sample 
size 
Wilcoxon signed 
rank test (T+) 
P Value 
B.T A.T diff 
Group A 1.57 0.24 1.33 1.00 
1.0  
 (2.0 - 1.0) 
49 1225.00 < 0.001 
Group B 1.92 1.44 0.48 0.00 
1.0  
 (1.0 - 0.0) 
48 171.00 < 0.001 
For group A, the median reduction in Kshudhaadhikya score after treatment is significant (P-value < 0.001) 
at 5% level of significance. i.e., it can be said that there is significant reduction in Kshudhaadhikya for Group 
A. For group B, the median reduction in Kshudhaadhikya score after treatment is significant (P-value < 
0.001) at 5% level of significance. i.e., in group B too, there is significant reduction in Kshudhaadhikya. 
Table no: 16: Comparative Analysis of Groups 
Group 
Median 
difference 
(bef–aft) 
Mean of 
difference 
(bef-aft) 
S.D. of 
difference 
(bef-aft) 
Mann-
Whitney U 
statistic 
P- Value 
Group A 1.00 1.33 0.47 1949.00 
 
< 0.001 
 Group B 0.00 0.48 0.71 
Reduction in Kshudhaadhikya score for group A was significantly higher than that in group B (p –value < 
0.001)at 5% level of significance. Thus, treatment A can be considered as more effective in reducing 
Kshudhaadhikyaas compared to treatment B.  
Table 17: Gradation wise distribution of patients 
Kshudhaadhikya 
0 1 2 3 
No. % No. % No. % No % 
Group A 
BT 1 2.00% 25 50.00% 20 40.00% 4 8.00% 
AT 38 76.00% 12 24.00% 0 0.00% 0 0.00% 
Group B 
BT 2 4.00% 15 30.00% 22 44.00% 11 22.00% 
AT 10 20.00% 15 30.00% 21 42.00% 4 8.00% 
Table 18: Kara-paadsuptata (Numbness) 
Group 
Mean score Median 
diff. 
IQR of diff. 
Q3 – Q1 
Sample 
size 
Wilcoxon signed 
rank test (T+) 
P Value 
B.T A.T diff 
Group A 1.69 0.43 1.27 1.00 
1.0  
 (2.0 - 1.0) 
49 1176.00 < 0.001 
Group B 1.75 1.33 0.42 0.00 
1.0  
 (1.0 - 0.0) 
48 210.00 < 0.001 
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For group A, the median reduction in suptata score after treatment is significant (P-value < 0.001) at 5% 
level of significance. i.e. it can be said that there is significant reduction in Suptata for Group A. For group B, 
the median reduction in Suptata score after treatment is significant (P-value < 0.001) at 5% level of 
significance. i.e. in group B too, there is significant reduction in Suptata. 
Table 19: Comparative Analysis of Groups 
Group 
Median 
difference 
(bef–aft) 
Mean of 
difference 
(bef-aft) 
S.D. of 
difference 
(bef-aft) 
Mann-
Whitney U 
statistic 
P- Value 
Group A 1.00 1.27 0.53 1968.00 
 
< 0.001 
 Group B 0.00 0.42 0.50 
Reduction in Suptata score for group A was significantly higher than that in group B (p –value < 0.001)at 5% 
level of significance. Thus, treatment A can be considered as more effective in reducing Suptata as compared 
to treatment B.  
Table 20: Gradation wise distribution of patients 
Suptata 
0 1 2 3 
No. % No. % No. % No % 
Group A 
BT 1 2.00% 22 44.00% 20 40.00% 7 14.00% 
AT 30 60.00% 19 38.00% 1 2.00% 0 0.00% 
Group B 
BT 2 4.00% 23 46.00% 14 28.00% 11 22.00% 
AT 8 16.00% 26 52.00% 10 20.00% 6 12.00% 
Table 21: Kara-paaddaha (Burning sensation of palms and soles) 
Group 
Mean score Median 
diff. 
IQR of diff. 
Q3 – Q1 
Sample 
size 
Wilcoxon signed 
rank test (T+) 
P Value 
B.T A.T diff 
Group A 1.62 0.44 1.19 1.00 
1.0  
 (2.0 - 1.0) 
48 990.00 < 0.001 
Group B 1.71 1.41 0.31 0.00 
1.0  
 (1.0 - 0.0) 
49 120.00 < 0.001 
For group A, the median reduction in Daha score after treatment is significant (P-value < 0.001) at 5% level 
of significance. i.e., it can be said that there is significant reduction in Daha for Group A. For group B, the 
median reduction in Daha score after treatment is significant (P-value < 0.001) at 5% level of significance. 
i.e. in group B too, there is significant reduction in Daha. 
Table 22: Comparative Analysis of Groups 
Group 
Median 
difference (bef–
aft) 
Mean of 
difference (bef-
aft) 
S.D. of 
difference (bef-
aft) 
Mann-
Whitney U 
statistic 
P- Value 
Group A 1.00 1.19 0.57 1991.50 
 
< 0.001 
 Group B 0.00 0.31 0.47 
Reduction in Daha score for group A was significantly higher than that in group B (p –value < 0.001)at 5% 
level of significance. Thus, treatment A can be considered as more effective in reducing Daha as compared to 
treatment B.  
Table 23: Gradation wise distribution of patients 
Kara-paad Daha 
0 1 2 3 
No. % No. % No. % No % 
Group A 
BT 2 4.00% 23 46.00% 20 40.00% 5 10.00% 
AT 29 58.00% 21 42.00% 0 0.00% 0 0.00% 
Group B 
BT 1 2.00% 24 48.00% 15 30.00% 10 20.00% 
AT 6 12.00% 25 50.00% 13 26.00% 6 12.00% 
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Table 24: Urine sugar 
Group 
Mean score 
Median 
diff. 
IQR of diff. 
Q3 – Q1 
Sample 
size 
Wilcoxon 
signed rank 
test (T+) 
P Value 
B.T A.T diff 
Group A 2.16 0.40 1.76 2.00 
1.0  
 (2.0 - 1.0) 
50 1275.00 < 0.001 
Group B 2.22 1.76 0.46 0.00 
1.0  
 (1.0 - 0.0) 
50 276.00 < 0.001 
For group A, the median reduction in Urine sugar score after treatment is significant (P-value < 0.001) at 5% 
level of significance. i.e. it can be said that there is significant reduction in Urine sugar for Group A. For group 
B, the median reduction in Urine sugar score after treatment is significant (P-value < 0.001) at 5% level of 
significance. i.e. in group B too, there is significant reduction in Urine sugar. 
Table 25: Comparative Analysis of Groups 
Group 
Median 
difference 
(bef–aft) 
Mean of 
difference 
(bef-aft) 
S.D. of 
difference 
(bef-aft) 
Mann-
Whitney U 
statistic 
P- Value 
Group A 2.00 1.76 0.59 2316.00 
 
< 0.001 
 Group B 0.00 0.46 0.50 
Reduction in urine sugar score for group A was significantly higher than that in group B (p –value < 0.001)at 
5% level of significance. Thus, treatment A can be considered as more effective in reducing urine sugar as 
compared to treatment B.  
Table 26: Gradation wise distribution of patients 
Urine sugar 
0 1 2 3 
No. % No. % No. % No % 
Group A 
BT 0 0.00% 5 10.00% 32 64.00% 13 26.00% 
AT 30 60.00% 20 40.00% 0 0.00% 0 0.00% 
Group B 
BT 0 0.00% 2 4.00% 35 70.00% 13 26.00% 
AT 0 0.00% 14 28.00% 34 68.00% 2 4.00% 
Fasting Blood Sugar Level  
Table 27: Decrease in Fasting Blood Sugar Level (Group A) 
Using paired t test, for Fasting Blood Sugar Level, p – value is less than 0.001 i.e. the difference between 
mean Fasting Blood Sugar Level before and after treatment is significant at 5% level of significance. i.e. we 
can say that There is decrease in Fasting Blood Sugar Level for group A. 
Table 28: Decrease in Fasting Blood Sugar Level (Group B) 
 
 
 
 
 
Using paired t test, for Fasting Blood Sugar Level, p – value is less than 0.001 i.e. the difference between 
mean Fasting Blood Sugar Level before and after treatment is significant at 5% level of significance. i.e. we 
can say that There is decrease in Fasting Blood Sugar Level for group B. 
 
Parameter 
Mean Score n 
 
SD SE (±) Paired “t” 
“p-value” (One 
tailed) B.T. A.T Diff. 
Fasting Blood 
Sugar Level 
184.80 159.74 25.06 50 16.45 2.33 10.77 < 0.001 
Parameter 
Mean Score 
n SD SE (±) Paired “t” 
“p-value” (One 
tailed) B.T. A.T Diff. 
Fasting Blood 
Sugar Level 
179.16 172.28 6.88 50 15.56 2.20 3.13 0.001 
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Table 29: Comparative analysis of groups 
Group 
Mean 
difference 
S.D. of 
difference 
n d.f. 
Two sample 
“t” 
P- value 
Group A 25.06 16.45 50 
98 8.739 < 0.001 
Group B 6.88 15.56 50 
The mean decrease in Fasting Blood Sugar Level for group A and mean decrease of group B was significantly 
different (P-value < 0.001) at 5% level of significance. Thus treatment A can be considered as more effective 
in decreasing Fasting Blood Sugar Level as compared to treatment B. 
Post-prandial Blood Sugar Level  
Table 30: Decrease in Post-prandial Blood Sugar Level (Group A) 
Using paired t test, for Post-prandial Blood Sugar Level, p – value is less than 0.001 i.e. the difference 
between mean Post-prandial Blood Sugar Level before and after treatment is significant at 5% level of 
significance. i.e. we can say that There is decrease in Post-prandial Blood Sugar Level for group A. 
Table 31: Decrease in Post-prandial Blood Sugar Level (Group B) 
Using paired t test, for Post-prandial Blood Sugar Level, p – value is less than 0.001 i.e. the difference 
between mean Post-prandial Blood Sugar Level before and after treatment is significant at 5% level of 
significance. i.e. we can say that There is decrease in Post-prandial Blood Sugar Level for group B.  
Table 32: Comparative analysis of groups 
Group 
Mean 
difference 
S.D. of 
difference 
n d.f. 
Two sample 
“t” 
P- value 
Group A 35.82 17.29 50 
98 7.86 < 0.001 
Group B 11.88 12.86 50 
The mean decrease in Post-prandial Blood Sugar Level for group A and mean decrease of group B was 
significantly different (P-value < 0.001) at 5% level of significance. Thus treatment A can be considered as 
more effective in decreasing Post-prandial Blood Sugar Level as compared to treatment B. 
Table 33: Comparative efficacy 
Parameter Group A Group B Comparative efficacy 
Polyuria Significant  Significant  Group A 
Polydipsia Significant  Significant  Group A 
Polyphagia Significant  Significant  Group A 
Numbness Significant  Significant  Group A 
Tingling Significant  Significant  Group A 
Urine sugar Significant  Significant  Group A 
BSL – fasting Significant  Significant  Group A 
BSL – PP Significant  Significant  Group A 
 
 
Parameter 
Mean Score n 
 
SD SE (±) Paired “t” 
“p-value” (One 
tailed) B.T. A.T Diff. 
Post-prandial Blood 
Sugar Level 
262.84 227.02 35.82 50 17.29 2.45 14.65 < 0.001 
Parameter 
Mean Score 
n SD SE (±) Paired “t” 
“p-value” (One 
tailed) B.T. A.T Diff. 
Post-prandial Blood 
Sugar Level 
244.00 232.12 11.88 50 12.86 1.82 6.53 < 0.001 
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Table 34:  comparison of improvement in both Groups  
Parameter 
Mean % improvement 
Group A Group B 
Polyuria 88.67% 24.33% 
Polydipsia 84.33% 22.00% 
Polyphagia 89.12% 25.69% 
Numbness 79.93% 25.35% 
Tingling 75.69% 19.05% 
Urine sugar 83.00% 19.33% 
BSL – fasting 13.21% 03.54% 
BSL – PP 13.56% 04.71% 
Overall Mean % improvement 65.94% 18.00% 
Overall Effect of Therapy 
While assessing overall efficacy of treatments, all assessment parameters were used. The criteria for 
assessment are as below. 
Table 36: Distribution of patients according to relief 
Overall Effect 
(patient wise) 
No. of patients 
Group A Group B 
Count % Count % 
Marked improvement 10 20.00% 00 00.00% 
Moderate improvement 37 74.00% 00 00.00% 
Mild improvement 03 06.00% 12 24.00% 
Unimproved 00 00.00% 38 76.00% 
Total 50 100.00% 50 100.00% 
In group A, 10 patients (20%) were observed with marked improvement, 37 patients (74%) were 
moderately improved while 3 were (6%) seen with mild improvement.  
In group B, 12 patients (24%) realized mild improvement while 38 patients (76%) were not 
improved.  
DISCUSSION 
In order to draw appropriate conclusion, it 
becomes inevitable to ponder over each fact and 
observation obtained from the study. This is 
achieved by the section of discussion over every 
aspect of the disease, the treatment and the 
observations. It will also help in better analysis and 
understanding of the subject. So, a discussion will 
be done in following three sections- 
Conceptual discussion 
Prameha is the disease of Tridosha 
predominance and Bahudrava Shlesma is the main 
element. Vata is the originator and executor of the 
all the functions of the body. The Vyanavayu is 
responsible for effective transport and circulation 
of all Bhavaib the body. Apanavayu is related to the 
functions of Pakvasaya and Basti and is responsible 
to hold and excrete the waste at proper time. In 
Prameha both types get vitiated leading to the 
abnormal pathway and excessive elimination 
respectively. Shlesma is basis for the structural 
integrity of the body and it provides sturdiness and 
strength in the body.  
All these function of Shlesma get hampered 
in the Prameha, due to increase of Dravaguna of 
Shleshma. When Kapha get vitiated it undoubtedly 
vitiates the body elements like Rasa, Mamsa, Meda, 
Vasa, Lasika, Oja.  
Pitta dosha, is mainly related with the 
digestion and metabolism. In case of Prameha, due 
to etiological factors, Pitta also get vitiated it and in 
turn affect the normal functions of Jathragni and 
Dhatwagni leading to the excessive formation of 
deranged quality Rasa, Mamsa, Meda etc. This in 
turn leads to the Dhatushaithilya and production of 
kleda. 
Thus in Prameha because of the above 
pathophysiological processes they i.e. Dusya 
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obstructs the normal pathway of Vata causing 
Avaran to it that in turns aggravate the Vyana leads 
to the transport of vital Dhatu Oja towards Basti 
where already aggravated Apana excretes out it 
from the body resulting depletion of Dhatus and 
generate disease Prameha. This pathogenesis 
mainly described by Charaka. Excess of deranged 
Shlesma, Meda, Kleda, Vasa, Lasika etc. aggravated 
vata produces various pahthophysiological changes 
in the body producing symptoms like Prabhata-
mutrata, Avilamutra, Pipasa, Daurbalya, Alasaya etc. 
leads to the structural as well as functional 
abnormalities in the body.  
Acharya Sushruta specifically mentioned 
that in Prameha the vitiated Doshas remains 
situated in the lower part of the body owing to the 
inefficiency of various Dhamanis i.e. vessels (Su.Chi. 
12/8). The Doshas should be eliminated through the 
nearest path. 
Mode of action of drug: According to Ayurveda, 
Samprapti Vighatana is the main basis for the 
treatment of every disease. In Prameha, the vitiated 
Kaphaand Pitta obstructs the path of Vata, causing 
its vitiation. Thus, the treatment should involve 
drugs that are effective in combating the ‘Drava’ 
guna of Shleshma, which is the first cause of the 
starting of the Samprapti. So, drug having Ruksha, 
Tikshna, Ushna properties would be of great use. 
Such drugs will also help in reduction of the 
excessive Kleda, which leads to Dhatushaithilya. 
The drug Somvalk, selected for the trial is 
having Tikta, Kasaya, Rasa Usna Veerya and Laghu, 
Ruksa Guna, Katu Vipaka and Kaphavatahara 
properties. 
Even the Aavaapdravyas used in the Basti 
preparation possess the same qualities and help in 
enhancing its action. Thus, Usna Veerya and Tikta 
Kasaya Rasa help to normalize the function of 
Jathragni and Dhatwagni. That in turn helps to form 
the Dhatus in proper proportion with Samyak 
qualities.  
Laghu Ruksa Guna helps for the Sosan of 
Bahudrava Shlesma and reduction of vitiated Meda 
Kleda. 
Thus once these factors get normalized in 
the body they in turn clear the Path of Vata which 
stops the depletion of vital Dhatus and restore 
normal physiology.  
Moreover, Somvalka is included in Moootra 
Sangrahaniyagana by Acharya Charaka. This also 
acts on the Mootravahastrotas and helps in reducing 
the symptoms like Prabhutmootrata and 
Avilmootrata. 
Mode of action of Basti: Basti is useful not only in 
disorders of Vaata, but also for Pitta, kapha and 
Rakta. It is also useful in Samsarga and 
sannipatajvyadhis. (su.chi 35/3) Similarly, Basti 
works according to its Veerya. So, use of Ushnavirya 
drugs in the Basti, makes the Basti itself 
Ushnaviryatmaka. Niruhabasti also acts as a 
Shodhan procedure (Doshanirharan), so it also 
qualifies as per the line of treatment of Prameha 
which states that first Shodhan should be 
undertaken in treating the Prameha. As Niruhabasti 
is better than Vaman or Virechan due to less 
complication, it seems to be the perfect choice for 
the treatment.  
Basti is proven to be effective to eliminate 
out the metabolic waste. It increases the Agni 
power. It also helps to normalise the function of 
Rasavaha, Medovaha, Mutravaha Srotasa. Basti 
drugs after absorption also helps to perform the 
Samprapti Vighatana, as they possess Pramehaghna 
quality. Anuvasana also due to Kasaya present in it 
acts against Meda and Kapha while Sneha helps to 
normalize the Vata. 
Thus Basti is helpful to reduce the excess of 
Kleda, purifies every channel, normalizes the 
function of Apana and Vyana and proves beneficial 
in Prameha. 
Discussion on Clinical trial: An open controlled 
clinical study was carried out. The total 100 number 
of patients diagnosed on the basis of inclusion 
criteria were divided into two groups.  
Group A- Trial group, 50 patients of trial 
group were administered Somvalkkashaybasti and 
Somvalk siddha anuvasanbasti along with their oral 
hypoglycemic drug Metformin in their prescribed 
dose and schedule for a period of 12 days.  
Group B- Control group, 50patients of 
Control Group were asked to continue to take their 
oral hypoglycemic drug Metformin in their 
prescribed dosage and schedule for a period of 12 
days. 
Follow up was taken on 13th day. The 
observations as made during the study, were 
subjected to suitable statistical tests for better 
analysis and for obtaining the result. 
General observations 
Age: It was observed from the present study that 
most of the patients (38%) of Prameha belonged to 
the age group of 45-50 years. The age group of 30-
34 years was the least affected group. This was 
observed because of in this age, there is natural 
aggravation of Vatadosha, which is the main factor 
in causation of any disease. 
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Sex: It was observed from the present study that 
maximum number of patients were males in both 
the groups. This is mainly due to demographic 
situation pertaining to this region. 
Religion: Most of the patients were Hindus (96%), 
while 4% patients were Muslims. This is also due to 
more number of Hindu residents in the study 
region.  
Habitat: Maximum patients were from rural area 
(86%). Remaining (14%) were from urban area. 
This is because the study has been conducted in 
rural area, so maximum number of patients were 
from rural habitat. 
Diet: Maximum patients were taking mixed diet 
(91%), while remaining were vegetarian. Excessive 
intake of nutritious diet is a prominent factor in 
Prameha. 
Nature of work: Most of the patients were having 
sedentary nature of work (49%). Least number of 
patients (14%) were involved in heavy work. Since 
most of the people lead modern life style which 
involves use of all types of comforts in home as well 
as at their place of work, this leads to over nutrition 
and occurrence of diseases.  
Prakruti: Maximum patients were Kapha-pittaj 
(27%) and Kapha-vatajprakruti (20%). Least 
patients were of Vaat-pittaj (3%) Prakruti. This 
indicates that the disease occurrence in more in 
Kapha dominant Prakrutis. 
Socioeconomic status: Maximum patients 
belonged to higher class (69%). Least number of 
patients belonged to lower class (12%). High 
socioeconomic status enables earning of all sorts of 
comforts and thus contributes in sedentary life, 
which is the cause of Prameha.  
Discussion of assessment parameters 
Polyuria: In group A, the mean score before 
treatment was 2.54 which reduced to 0.30 after 
treatment.  
In group B, the mean score before treatment 
was 2.36 which reduced to 1.68 after treatment. 
The difference in mean score before and 
after treatment observed in group A was 2.24, 
whereas in group B it was only 1.68. 
Thus, the result in Group A was more significant 
than Group B. 
The significant result in group A, indicates 
that the Somvalkkashay Basti acts on the 
Mootravahastrotas, it also is able to reduce the 
Kleda.  
Polydipsia: In group A, the mean score before 
treatment was 2.34 which reduced to 0.42 after 
treatment.  
In group B, the mean score before treatment 
was 2.24 which reduced to 1.70 after treatment. 
The difference in mean score before and after 
treatment observed in group A was 1.92, whereas in 
group B it was only 0.54. 
Thus, the result in Group A was more 
significant than Group B. 
The decrease in polydipsia is probably due 
to decrease in polyuria, as the hydration is 
maintained due to less frequency of passing urine.  
Polyphagia: In group A, the mean score before 
treatment was 1.57 which reduced to 0.24 after 
treatment.  
In group B, the mean score before treatment 
was 1.92 which reduced to 1.44 after treatment. 
The difference in mean score before and after 
treatment observed in group A was 1.33, whereas in 
group B it was only 0.48. 
Thus, the result in Group A was more 
significant than Group B. 
The reduction in Dhatuagnimandya leads to 
the formation of good quality of Dhatus and thereby 
proper nutrition of body, so as nutrition can be 
achieved within the limited amount of food, there is 
reduction in the demand of food by the body. The 
decrease in polyphagia indicates correction of 
Jatharagni of the patients. It is also the Lakshana of 
Samyak yoga of Basti therapy.  
Kar-paadsuptata (Polyneuritis): In group A, the 
mean score before treatment was 1.69 which 
reduced to 0.43 after treatment. In group B, the 
mean score before treatment was 1.75 which 
reduced to 1.33 after treatment. The difference in 
mean score before and after treatment observed in 
group A was 1.27, whereas in group B it was only 
0.42. 
Thus, the result in Group A was more 
significant than Group B. 
Suptata is the symptom of vitiated Kapha 
and after the treatment, the Kaphashamak action of 
the Somvalk helps to reduce this symptom of 
Suptata.  
Kara-paaddaha (burning sensation of palms and 
soles) 
In group A, the mean score before treatment 
was 1.62 which reduced to 0.44 after treatment. In 
group B, the mean score before treatment was 1.71 
which reduced to 1.41 after treatment. The 
difference in mean score before and after treatment 
observed in group A was 1.19, whereas in group B it 
was only 0.31. 
Thus, the result in Group A was more significant 
than Group B. 
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Urine sugar: In group A, the mean score before 
treatment was 2.16 which reduced to 0.40 after 
treatment. In group B, the mean score before 
treatment was 2.22 which reduced to 1.76 after 
treatment. The difference in mean score before and 
after treatment observed in group A was 1.76, 
whereas in group B it was only 0.46. 
Thus, the result in Group A was more 
significant than Group B. 
The reduction in urine sugar is due to reduction in 
the blood sugar level. 
Fasting Blood Sugar Level: In group A, the mean 
score before treatment was 184.80 which reduced 
to 159.74 after treatment. In group B, the mean 
score before treatment was 179.16 which reduced 
to 172.28 after treatment. The difference in mean 
score before and after treatment observed in group 
A was 25.06, whereas in group B it was only 6.88. 
Thus, the result in Group A was more 
significant than Group B. 
Post Prandial Blood Sugar Level: In group A, the 
mean score before treatment was 262.84 which 
reduced to 227.02 after treatment. In group B, the 
mean score before treatment was 244 which 
reduced to 232.12 after treatment. The difference in 
mean score before and after treatment observed in 
group A was 35.82, whereas in group B it was only 
11.88. 
Thus, the result in Group A was more 
significant than Group B. 
The reduction in fasting and post prandial 
blood sugar levels is due to the correction of 
Dhatvagni i.e., correction in metabolism of the food 
taken. 
Total effect of the therapy 
Polyuria: The mean percentage of improvement in 
group A was 88.67% as compared to 24.33% in 
group B. 
Polydipsia: The mean percentage of improvement 
in group A was 84.33% as compared to 22% in 
group B. 
Polyphagia: The mean percentage of improvement 
in group A was 89.12% as compared to 25.69% in 
group B. 
Kara-paadsuptata (Numbness): The mean 
percentage of improvement in group A was 79.93% 
as compared to 25.35% in group B. 
Kara-paaddaha (burning sensation of palms and 
soles): The mean percentage of improvement in 
group A was 75.69% as compared to 19.05% in 
group B. 
Urine sugar: The mean percentage of improvement 
in group A was 83% as compared to 19.33% in 
group B. 
BSL-Fasting: The mean percentage of improvement 
in group A was 13.21% as compared to 03.54% in 
group B. 
BSL- PP: The mean percentage of improvement in 
group A was 13.56% as compared to 04.71% in 
group B. 
Overall Effect of Therapy 
Distribution of patients according to relief: In 
Group A, 20% of patients showed marked 
improvement; the highest 74% showed moderate 
improvement; 6% of patients showed mild 
improvement while, none were left unimproved. In 
Group B, none of the patients showed marked or 
moderate improvement, 24% of the patients 
showed mild improvement and most of the patients 
i.e., 76% showed no improvement. So, it can be 
concluded from above that Group A showed 
moderate improvement, while Group B showed no 
improvement. The overall result obtained in the 
present study shows 65% improvement in Trial 
group which is moderate improvement according to 
the overall assessment criteria, whereas there was 
only 18% improvement in the Control group which 
falls within unimproved category according to the 
overall assessment criteria. The unimproved 
condition in the Control group was recorded, as the 
patients of this group were taking the OHA 
Metformin according to their need and as per their 
prescription. The little variation which was 
observed in the Control group is negligible and can 
be attributed to variation within the normal range. 
The moderate improvement in the Trial group 
indicates that, apart from the effects of OHA, the 
Basti therapy also had a positive impact on the 
signs and symptoms of the patients, which is 
reflected in the much higher result in Trial group as 
compared to the control group. This can be justified 
because, there was an no intervention as such in the 
Group B, while the Basti therapy showed its add-on 
effect in the patients of Group A. 
CONCLUSION 
The trial drug in the study i.e., Somvalk 
kasha Asthapanbasti has proved significantly 
effective in symptoms like Polyuria, polydipsia, 
polyphagia and urine sugar. It has shown moderate 
effects on the symptoms like numbness and 
tingling. It has shown mild improvement in 
parameters of BSL- Fasting and BSL- PP 
The ‘Somvalk kashay asthapan basti’ can be 
used as adjuvant therapy along with, diet control 
and exercise as first line of treatment. It can be 
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useful as a preventive measure in case of pre 
diabetics after further research on pre diabetics. 
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